ARIA: Summary for ARIAD Pharmaceuticals, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 6:18am EST - Canadian Markets open in 3 hours and 12 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Ariad Pharmaceuticals Inc. (ARIA)

On Feb 9: 2.35 USD 0.00 (0.00%)

MORE ON ARIA

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

ARIAD Pharmaceuticals, Inc. (NGM:ARIA) Delayed quote data

Last Trade:	2.35 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	2.35
Open:	N/A
Bid:	1.51 x 100
Ask:	2.88 x 100
1y Target Est:	5.00

Day's Range:	N/A - N/A
52wk Range:	0.97 - 3.48
Volume:	0
Avg Vol (3m):	1,958,730
Market Cap:	256.05M
P/E (ttm):	N/A
EPS (ttm):	-0.94
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add ARIA to Portfolio

Download Data

HEADLINES

•	ARIAD to Present at the 12th Annual BIO CEO & Investor Conference
	Business Wire (Thu, Jan 28)

•	ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year
	EDGAR Online (Fri, Jan 22)

•	ARIAD to Present at the 28th Annual J.P. Morgan Healthcare Conference
	Business Wire (Mon, Jan 4)

•	Top Ten '09 Clone Portfolios
	at Seeking Alpha (Sun, Jan 3)

•	5 Cold Stocks Heating Up
	at Motley Fool (Mon, Dec 28)

•	This Year's Upside Crash & 3 PowerRatings Stocks
	TradingMarkets.com (Mon, Dec 21)

•	Friday Options Update: SVNT, JBLU, ROST, RVSN, MRVL, RYL, ARIA, WLP
	at Seeking Alpha (Fri, Dec 18)

•	Friday Options Update: MRVL, RYL, ARIA, WLP
	at Seeking Alpha (Fri, Dec 18)

•	Ariad rounds out phase 3 cancer study
	at bizjournals.com (Fri, Dec 18)

•	ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
	EDGAR Online (Thu, Dec 17)

•	ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
	Business Wire (Thu, Dec 17)

•	ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
	EDGAR Online (Tue, Dec 15)

•	ARIAD Announces Updated Data from Clinical Trial of Its Investigational mTOR Inhibitor, Ridaforolimus, In Combination with Trastuzumab
	Business Wire (Mon, Dec 14)

More Headlines for ARIA...

ANALYST

EPS Est (next year) (Dec-09) :	-0.84
EPS Est (in 2 years) (Dec-10) :	-0.63
Avg Rec (current)*:	1.4
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer in the United States and Europe.

Full Company Profile

Add to Portfolio

Email to a Friend

•